Understand the source comparison
SS-LUP-332 Myths Cost Money Health: Comparison of Claims vs Evidence
'Replicates endurance training without exercise' Increases mitochondrial density and oxidative enzyme expression. Adaptations only translate to performance when paired with actual energy demand Preclinical rodent data only. No human trials demonstrating exerci
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 'Replicates endurance training without exercise'
- Increases mitochondrial density and oxidative enzyme expression. Adaptations only translate to performance when paired with actual energy demand
- Preclinical rodent data only. No human trials demonstrating exercise-free performance gains
- Compound may enhance training adaptation or recovery capacity, not replace training stimulus itself
- Overstated. Mechanism requires cellular stress signals to produce functional outcomes
- 'Burns fat directly through pathway activation'
- Shifts substrate preference toward fatty acid oxidation by upregulating beta-oxidation enzymes. Requires energy deficit or flux to activate
- Gene expression data in vitro and in vivo. No controlled trials showing fat loss without caloric deficit
- Without exercise or dietary restriction, increased oxidative capacity doesn't drive net fat reduction
- Mechanistically unsupported. ERR agonism optimises fuel use during demand, doesn't create demand
- 'Works at mouse mg/kg doses scaled directly to humans'
- Allometric scaling adjusts for metabolic rate and surface area differences. Human equivalent dose is ~12% of direct mg/kg conversion
- FDA HED formula widely accepted. Direct scaling ignores pharmacokinetic principles
- Using unadjusted doses wastes 85–90% of procured compound and increases off-target risk
- Dosing error. Leads to budget waste and protocol invalidation
- 'Stable at room temperature for weeks after reconstitution'
- Lyophilised powder stable at −20°C; reconstituted solution degrades rapidly above 8°C through hydrolysis
- Stability data from peptide degradation studies. Temperature excursions cause irreversible potency loss
- Improper storage renders compound inactive within days. Results become unreliable
- Storage failure. Most common cause of inconsistent results in SLU-PP-332 protocols